However, contrasting with the gain-of function effect caused by RET mutations in MTC, loss-of-function RET mutations account for approximately 50% of familial and 7–35% of sporadic HSCR patients [24,25]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.